Arkosy, Peter

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355